Lyka Labs Limited (BOM:500259)
India · Delayed Price · Currency is INR | Market Cap | 2.76B |
| Revenue (ttm) | 1.33B |
| Net Income (ttm) | 19.37M |
| Shares Out | n/a |
| EPS (ttm) | 0.55 |
| PE Ratio | 142.64 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 568 |
| Average Volume | 3,900 |
| Open | 83.01 |
| Previous Close | 81.04 |
| Day's Range | 77.32 - 83.50 |
| 52-Week Range | 77.32 - 175.95 |
| Beta | n/a |
| RSI | 35.47 |
| Earnings Date | Nov 12, 2025 |
About Lyka Labs
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti... [Read more]
Financial Performance
Financial StatementsNews
Lyka Labs shares fall 3% as Q1 net profit falls 20% YoY; Check earnings
Shares of Lyka Labs Ltd. fell by 2.82% to ₹112.90 on Thursday afternoon following the company’s Q1 FY26 earnings announcement, which revealed a 20% year-on-year drop in net profit. Q1 FY26 Highlights ...
Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain
Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitm...